DOC

HIGHEST PRIORITY CHALLENGE TOPICS

By Jon Adams,2014-06-17 18:43
27 views 0
HIGHEST PRIORITY CHALLENGE TOPICS

     HIGHEST PRIORITY CHALLENGE TOPICS

Topics in the table below that are marked with an asterisk (*) have been designated as the

    Institute, Center or Office’s highest priority; however, applicants may apply to any of the topics

    listed in the Omnibus.

Note: Applicants are also encouraged to review the compilation of all NIH

    Institute and Center Challenge Topics:

    http://grants.nih.gov/grants/funding/challenge_award/Omnibus.pdf

    Broad Challenge Area .................................................................................................. 10 Specific Challenge Topic .............................................................................................. 10 (01) Behavior, Behavioral Change, and Prevention ................................................... 10 01-AA-101* Identifying Phenotypic Markers for Positive Behavior Change. ............ 10 01-AA-102* Functional Roles of Neuroimmune Factors in Mediating Behavior. ...... 10 01-AA-103* Capturing Social Network Information for Groups at High Risk for

    Negative Health Behaviors. .............................................................. 10 01-GM-101* Individual-based model of social behavior. ....................................... 10 01-OD(OBSSR)-101* Tools for studying cultural phenomena. ............................... 10 01-OD(OBSSR)-102* Methods for studying the interactions among behaviors,

    environments, and genetic/epigenetic processes. ............................... 10 01-OD-101* Test default options to promote healthier behaviors. ............................. 11 01-TW-101* Novel strategies to improve health care access for stigma-related

    conditions. ........................................................................................ 11 01-TW-102* Improving health through ICT/mobile technologies: enhancing patient

    compliance. ...................................................................................... 11 (02) Bioethics ............................................................................................................... 11 02-HG-101* Informed consent and data access policies. ........................................... 11 02-OD(OSP)-101* Unique Ethical Issues Posed by Emerging Technologies. ......... 11 02-OD(OSP)-102* Ethical Issues in Health Disparities and Access to Participation

    in Research. ...................................................................................... 12 02-OD(OSP)-103* Ethical Issues Associated with Electronic Sharing of Health

    Information. ...................................................................................... 12 02-OD(OSP)-104* Ethical Issues in the Translation of Genetic Knowledge to

    Clinical Practice. ............................................................................... 13 02-OD(OSP)-105* Ethical Issues Raised by the Blurring between Treatment and

    Research. .......................................................................................... 13 02-RR-101* Recontact Issues in Genotype and Genome-Wide Association Studies. . 14 (03) Biomarker Discovery and Validation .................................................................. 14 03-AR-101* Biomarkers Of Persistent Damage After Acute Joint Injury. ................. 14

    1

     Develop Novel Imaging, Proteomic, Or Genomic Approaches To Identify 03-AR-102*

    Risk For Fragility Fractures. ............................................................. 14 03-AT-101* Psychoneuroimmunology biomarkers of stress. ................................. 14 03-AT-102* Antioxidant biomarkers. ....................................................................... 15 03-DA-101* Biomarkers for Pain. ............................................................................. 15 03-DA-102* Novel Molecular Targets From Unexpected Sources. ............................ 15 03-DA-103* Comprehensive biomolecular mass spectrometry .................................. 15 03-DA-104* Biosignatures of Drug Exposure. .......................................................... 15 03-HL-101* Identify and validate clinically relevant, quantifiable biomarkers of

    diagnostic and therapeutic responses for blood, vascular, cardiac, and

    respiratory tract dysfunction.............................................................. 16 03-MH-101* Biomarkers in mental disorders. ............................................................ 16 03-NS-101* Identification and validation of biomarkers for Proof of Concept (early

    Phase IIa) studies for Nervous System Disorders. ............................. 16 03-OD(OBSSR)-101* Developing high-throughput biomarker assays from finger-

    stick dried blood spots. ..................................................................... 16 03-OD(ORDR)-101* Validating biomarkers for functional outcomes in rare diseases.

     16

    (04) Clinical Research ................................................................................................. 17 04-AA-101* Medication Development for Hepatic Fibrosis. ..................................... 17 04-AG-101* Therapeutic algorithms for older patients with multiple conditions: data

    analyses and pilot testing. ................................................................. 17 04-AI-101* Develop novel methods and address key questions in mucosal

    immunology: .................................................................................... 17 04-AI-102* The human immune response to infection and immunization Profiling

    via modern immunological methods and systems biology. ................ 17 04-AR-101* Autoimmunity For Diseases Of The Skin, Joints, Muscle And Other

    Tissues. ............................................................................................. 18 04-DC-101* Prevention of Otitis Media. ................................................................... 18 04-DK-101* Role of the human gut microbiome in NIDDK diseases. ....................... 18 04-GM-101* Personalized drug response and toxicity. ........................................... 18 04-HD-101* Identify the Factors that Place Women at Risk for Preterm Birth. ...... 18 04-HD-102* Development of Pediatric Medical Devices. .......................................... 18 04-MD-101* Development of effective approaches to increase minority recruitment

    and retention into clinical trials. ........................................................ 19 04-MH-101* Autism: Addressing the challenge. ........................................................ 19 04-NR-101* Integrating Cost-Effectiveness Analysis into Clinical Research ......... 19

    2

     Methods to Enhance Palliative Care and End-of-Life Research ......... 19 04-NR-102*

    04-NR-103* Improving Quality of Life of Patients and Family Following a War-

    Related Traumatic Injury. ................................................................. 19 04-OD-101* Develop and validate behavioral metrics to measure the impact of chronic

    pain. ................................................................................................. 19 04-TW-101* Examining the clinical and mechanistic link between diabetes mellitus

    and cardiovascular disease in low- and middle-income countries. ..... 20 (05) Comparative Effectiveness Research .................................................................. 20 05-AA-101* Innovative Analyses of Existing Clinical Datasets. ............................... 20 05-AA-102* Adaptive Designs and Person-Centered Data Analysis for Alcohol

    Treatment Research. ......................................................................... 20 05-AA-103* Use of Innovative Technologies in Alcohol Treatment Research. .......... 20 05-AG-101* Data Infrastructure for Post-Marketing Comparative Effectiveness

    Studies. ............................................................................................. 21 05-AG-102* Prevention and Risk Factor Reduction Strategies for Disabilities. ..... 21 05-AG-103* Imaging and Fluid Biomarkers for Early Diagnosis and Progression of

    Aging-related Diseases and Conditions including Neurodegenerative

    Diseases. ........................................................................................... 22 05-AG-104* Planning Grants and Pilot Studies for Comparisons of Management

    Strategies for Older Patients with Multiple Coexisting Conditions. ... 22 05-AG-105* Comparative Intervention Trials for Diseases and Syndromes of Aging

    Including Neurodegenerative Diseases. ............................................. 22 05-AI-101* Accelerated Aging in Treated vs. Untreated HIV/AIDS. ....................... 23 05-AI-102* Comparative-effectiveness of ART. ...................................................... 23 05-AI-103* Clinical Research to Reduce the Risk of Antimicrobial Resistance........ 23 05-AR-101* Comparativeness Effectiveness (CE) of Biologics in Autoimmune

    Rheumatic and Skin Diseases............................................................ 23 05-AR-102* Comparative Effectiveness (CE) of Treatments for Chronic Childhood

    Arthritis and Musculoskeletal (MSK) and Skin Disease. ................... 23 05-AR-103* Comparative Effectiveness of Therapies to Treat Fibromyalgia......... 24 05-AT-101* Comparative Effectiveness Studies of Non-Pharmacological Treatments

    for Chronic Low Back Pain. .............................................................. 24 05-AT-102* Comparative Effectiveness Studies of Complementary and Alternative

    Medicine. .......................................................................................... 24 05-CA-101* Comparative Effectiveness Research in Cancer Primary Prevention. ..... 24 05-CA-102* Comparative Effectiveness Research on Cancer Screening................ 24 05-CA-103* Cost-Effectiveness of Patient Navigation. ......................................... 25 05-CA-104* Comparative Effectiveness Research on Cancer Treatment. .............. 25

    3

     CISNET. ........................................................................................... 25 05-CA-105*

    05-DA-101* Behavioral and Medication Interventions To Treat Drug Abuse

    Disorders in Non-Specialty Care Settings. ........................................ 26 05-DA-103* Integrated vs. Separate Treatment of Substance Abuse and Comorbid

    Conditions. ....................................................................................... 26 05-DA-104* Comparing Drug Treatment Effectiveness in Ethnic Minority

    Populations. ...................................................................................... 26 05-DA-105* Comparing Episodic and Continuous Care for Drug Abuse Treatment.

     27

    05-DE-101* Validating dental caries risk assessment guidelines. .......................... 27 05-DE-102* Treatment of tobacco and drug dependence in dental settings............ 27 05-DE-103* Treatment and Outcomes Cleft Palate/Cleft Lip Anomalies............... 27 05-DE-104* Adjunctive techniques for detection of oral premalignant and

    malignant lesions. ............................................................................. 28 05-DE-105* Infrastructure for Comparative Effectiveness Studies in Oral Health and

    Craniofacial Conditions. ................................................................... 28 05-DK-101* Selecting the Optimal Initial Treatment Regimen for Patients With

    Newly Discovered Type 2 Diabetes. ................................................. 28 05-DK-102* Understanding the Effects of Bariatric Surgery on Type 2 Diabetes and

    Cardiovascular Risk Factors.............................................................. 29 05-DK-103* Antihypertensive Drugs and Level of Blood Pressure Control in

    Hemodialysis Patients. ...................................................................... 29 05-DK-104* Fascial Versus Mid-Urethral Sling Surgery in Stress Urinary

    Incontinence Treatment Failures. ...................................................... 29 05-DK-105* Medical Treatment of Calcium Stones: Calcium Stone Trial ............. 30 05-EB-101* Comparative Effectiveness of Advanced Imaging Procedures ............ 30 05-EB-102* Screening Methodologies for Breast Cancer ....................................... 30 05-EB-103* Comparative Effectiveness of Non-Invasive Ultrasound Techniques .. 30 05-EB-104* Comparative Effectiveness of Robotic Surgery - ................................... 30 05-EB-105* Comparative Effectiveness of Medical Implants. .............................. 31 05-EY-101* Treatment of Age Related Macular Degeneration and Diabetic Eye

    Diseases and Disorders. .................................................................... 31 05-EY-102* Treatment of Pediatric Eye Diseases and Disorders. .......................... 31 05-EY-103* Eye and Vision Systematic Reviews. ................................................ 31 05-GM-101* Anesthesiology Clinical Pharmacology Sepsis Trauma, Burn, and Peri-

    operative Injury Wound Healing. ...................................................... 31 05-HL-101* Treatment of atrial fibrillation. .............................................................. 32

    4

     Treatment of obstructive sleep apnea. ................................................... 32 05-HL-102*

    05-HL-103* Treatment of mild persistent asthma in children. ................................... 32 05-HL-104* Reducing cardiovascular risk in moderate-risk and asymptomatic patients.

     ......................................................................................................... 32 05-HL-105* Optimizing of anti-platelet treatment after revascularization procedures.

     ......................................................................................................... 33 05-LM-101* Effect of “Information Prescriptions” on Improving Care by Increasing

    Compliance with Medication Protocol Given to Discharged

    Emergency Department Patients. ...................................................... 33 05-LM-102* Ability of Decision Tools in an Electronic Health Care System to

    Increase Use of Generic Drugs. ......................................................... 33 05-LM-103* Improving Compliance of School Children with Immunization

    Schedules.......................................................................................... 34 05-LM-104* Value of “Virtual Reality” Interaction in Improving Compliance with

    Diabetic Regimen. ............................................................................ 34 05-MD-101* Social Determinants of Health. ......................................................... 34 05-MD-102* Prevention of Chronic Diseases in Disparity Populations. ................. 34 05-MD-104* Screening of Health Disparity Conditions. ........................................ 35 05-MD-105* Health Literacy. ................................................................................ 35 05-MH-101* Leveraging Existing Healthcare Networks for Comparative Effectiveness

    Research on Mental Disorders and Autism. ....................................... 35 05-MH-102* Cost Effectiveness of Mental Health Interventions. ............................... 35 05-MH-103* Collaboration with AHRQ Comparative Effectiveness Research Program.

     ......................................................................................................... 35 05-NS-101* Consortia Building for Comparative Effectiveness Research in Clinical

    Neuroscience. ................................................................................... 36 05-NS-102* Technologies to Enable Comparative Effectiveness Research in

    Clinical Neuroscience ....................................................................... 36 05-NS-103* Validating NIH’s New Clinical Tools in Populations With

    Neurological Disorders ..................................................................... 37 05-NS-104* Intervention vs. Best Medical Therapy in Asymptomatic Persons With

    Identified Vascular Abnormalities. .................................................... 37 05-RR-101* Build CER Capacity Through Education. .......................................... 37 05-RR-102* Support Pilot CER Projects in Community Settings. ......................... 37 (06) Enabling Technologies ......................................................................................... 37 06-AG-101* Neuroscience Blueprint: Development of non-invasive imaging

    approaches or technologies that directly assess neural activity. ......... 37 06-AT-101* Imaging correlates of brain states. ..................................................... 38

    5

     Develop Improved Hearing Devices. .................................................... 38 06-DC-101*

    06-DC-102* Develop and Validate Methods for Delivery of Drugs and Molecules to

    the Inner Ear. .................................................................................... 38 06-DK-101* Development of cell-specific delivery systems for therapy and imaging.

     ......................................................................................................... 38 06-DK-102* Mechanisms and measurement of human thermogenesis. ...................... 39 06-EB-101* Development of minimally invasive image-guided systems. ............. 39 06-EB-102* Development of biomedical technologies and systems. ......................... 39 06-ES-101* Measuring the body burden of emerging contaminants: Biosensors and

    lab “on-chip” technology for measuring in vivo environmental agents

     ......................................................................................................... 39 06-ES-102* 3-D or virtual models to reduce use of animals in research: Creation of

    miniature multi-cellular organs for high throughput screening for

    chemical toxicity testing. .................................................................. 39 06-GM-101* Structural analysis of macromolecular complexes. ................................ 39 06-GM-103* Development of predictive methods for molecular structure,

    recognition, and ligand interaction. ................................................... 40 06-HD-101* Improved interfaces for prostheses to improve rehabilitation outcomes.

     40

    06-HG-101* New computational and statistical methods for the analysis of large

    data sets from next-generation sequencing technologies. ................... 40 06-HG-102* Technologies for obtaining genomic, proteomic, and metabolomic data

    from individual viable cells in complex tissues. ................................ 40 06-LM-101* Intelligent Search Tool for Answering Clinical Questions. ................ 41 06-LM-102* Self-documenting encounters. ........................................................... 41 06-MD-101* Development of Telehealth Tools to Promote Health and Connect At-

    Risk Youth to the Health System via Low-Cost, Mobile, and Wireless

    Technologies. ................................................................................... 41 06-OD(OBSSR)-101* Using new technologies to improve or measure adherence. . 41 06-OD-101* Development of new tools and technologies to interrogate human

    mitochondrial function in vivo. ......................................................... 42 06-RR-101* Virtual environments for multidisciplinary and translational research. .. 42 06-RR-102* Infrastructure for biomedical knowledge discovery. .............................. 42 (07) Enhancing Clinical Trials .................................................................................... 42 07-CA-101* Novel Agents for Cancer Treatment. ..................................................... 42 07-EY-101* Cost Effectiveness/Quality of Life: Tools to assess the impact of

    interventions on quality-of-life and cost effectiveness of ophthalmic

    treatments. ........................................................................................ 42

    6

     Developing technology to increase efficiency and decrease cost of 07-NS-101*

    clinical trials. .................................................................................... 43 07-OD(OBSSR)-101* Improving and/or assessing external validity in randomized

    clinical trials (RCTs). ........................................................................ 43 07-OD(ORDR)-101* Library of standardized patient registry questions. ................ 43 07-OD(ORDR)-102* Rare disease genetic patient registry. ................................... 43 (08)Genomics ............................................................................................................... 43 08-AG-101* Genetic factors affecting rates of change in disease risk factors with age.

     ......................................................................................................... 43 08-CA-101* Augmenting Genome-Wide Association Studies. .................................. 44 08-DE-101 * Planning Grants for Genome-wide Studies of Understudied Oral and

    Craniofacial Diseases and Disorders [Temporomandibular Joint

    Disorder, Oral Cancer, Sjögren’s Syndrome, Periodontal Disease]: ... 44 08-EY-101* Genomics of complex eye diseases. ...................................................... 44 08-HG-101* Technology and resources for high-throughput functional analysis of

    functional elements in genomic sequences. ....................................... 44 08-HL-101* Identify causal genetic variants associated with heart, lung, and blood

    diseases by application of targeted DNA capture and massively

    parallel sequencing technologies followed by selective genotyping of

    DNA samples from large well-phenotyped populations. .................... 45 08-MH-101* Beyond GWAS: Deep sequencing of mental disorders. ......................... 45 08-MH-102* Schizophrenia interactome. ................................................................... 45 08-NR-101* Genetic and Epigenetic Predictors of Symptom Severity. ...................... 45 08-NS-101* Cross-disease research to identify mechanisms common to Mendelian

    disorders of low incidence and genetically complex, high incidence

    disorders. .......................................................................................... 46 (09) Health Disparities................................................................................................. 46 09-AG-101* Geographic Disparities in Medicare Usage and Cost. ............................ 46 09-MD-101* Creating Transformational Approaches to Address Rural Health

    Disparities. ....................................................................................... 46 09-MD-102* Trans-disciplinary Research to Integrate the Biological and Non-

    biological Determinants of Health to Address Health Disparities. ..... 46 09-MD-103* Initiating Innovative Interventions to Prevent Family Violence. ........ 47 (10) Information Technology for Processing Health Care Data ................................ 47 10-CA-101* Cyber-Infrastructure for Health: Building Technologies to Support Data

    Coordination and Computational Thinking. ...................................... 47 10-EB-101* Engineering improved quality of health care at a reduced cost. ......... 47

    7

     Develop data sharing and analytic approaches to obtain from large-scale 10-HL-101*

    observational data, especially those derived from electronic health

    records, reliable estimates of comparative treatment effects and

    outcomes of cardiovascular, lung, and blood diseases . ..................... 47 10-LM-101* Informatics for post-marketing surveillance. ..................................... 48 10-LM-102* Advanced decision support for complex clinical decisions. ............... 48 10-OD-101* Adapt existing genetic and clinical databases to make them interoperable

    for pharmacogenomics studies. ......................................................... 48 10-RR-101* Information Technology Demonstration Projects Facilitating Secondary

    Use of Healthcare Data for Research ................................................. 48 10-TW-101* Innovative information and communication technologies to enhance

    capabilities of U.S. institutions in global health research and research

    training. ............................................................................................ 49 (11) Regenerative Medicine ......................................................................................... 49 11-DC-101* Hair Cell Regeneration and Maintenance. ......................................... 49 11-EB-101* Vascular networks in engineered tissues. .......................................... 49 11-HL-101* Develop cell-based therapies for cardiovascular, lung, and blood diseases.

     ......................................................................................................... 49 (12) Science, Technology, Engineering and Mathematics Education (STEM) ......... 50 12-OD-101* Efficacy of educational approaches toward promoting STEM

    competencies. ................................................................................... 50 (13) Smart Biomaterials - Theranostics ...................................................................... 50 13-DE-101* Novel Self-Healing Smart Dental and Bio-Restorative Materials: ..... 50 13-EB-101* Theranostics: Combined delivery of diagnostic and therapeutic agents.

     ......................................................................................................... 50 13-ES-101* Methods to evaluate the health and safety of nanomaterials. ................. 50 (14) Stem Cells ............................................................................................................. 50 14-AG-101* Induced Pluripotent Stem (iPS) Cells for Aging and Neurodegeneration

    Research. .......................................................................................... 50 14-AR-101* Delineate Factors That Control The Differentiation Of Pluripotent

    Stem Cells In The Skin And Musculoskeletal System Into Different

    Lineages. .......................................................................................... 51 14-DE-101* Precise Reprogramming of Cells from Oral and Craniofacial Tissues: .. 51 14-DK-101* Induced pluripotent stem cells--cellular and humanized mouse models of

    disease. ............................................................................................. 51 14-EY-101* Development of stem cell treatment for degenerative diseases of the eye.

     ......................................................................................................... 51 14-MH-101* Developing iPS cells for mental disorders. ............................................ 52

    8

     Reverse engineering human neurological disease. ............................. 52 14-NS-101*

    (15) Translational Science ........................................................................................... 52 15-AA-101* Determining If and How Adolescent Behaviors Affect Connections in the

    Developing Brain. ............................................................................. 52 15-AI-101* Explore the earliest events in HIV infection and use this information to

    develop new interventions for preventing and treating HIV infection:

     ......................................................................................................... 52 15-AI-102* Develop diagnostics and drugs for multiple or extensively drug-resistant

    tuberculosis (MDR/XDR TB): .......................................................... 53 15-AI-103* Develop drugs for neglected tropical diseases, with a special emphasis

    on malaria: ........................................................................................ 53 15-CA-101* The Role of Cellular Architecture in Normal and Tumor Cell Biology. . 53 15-CA-102* Understanding mechanisms of hormone refractory cancers for therapeutic

    targeting. .......................................................................................... 53 15-DA-101* Novel Approaches to Improve Immunogenicity of Vaccines Against

    Small Molecules ............................................................................... 54 15-DE-101* Molecular Profiling and Developing Mouse Models for Salivary Gland

    Tumor Research: .............................................................................. 54 15-DE-102* New Models and Measures in Pre-clinical Chronic Pain Research: ... 54 15-DK-101* Identification of bioactive macronutrients in the diet that impact

    metabolic state. ................................................................................. 54 15-ES-101* Effects of environmental exposures on phenotypic outcomes using non-

    human models. .................................................................................. 54 15-EY-101* Protein misfolding in degenerative diseases of the eye. ......................... 55 15-HD-101* Developing New Antimicrobials from Oligosaccharides. .................. 55 15-HD-102* Pelvic Pain. ....................................................................................... 55 15-LM-101* Presenting genome information in electronic health records. ............. 55 15-NR-101* NIH Partners in Research Program: Pathways for Translational

    Research. .......................................................................................... 55 15-NS-101* Manipulating the blood-brain-barrier to deliver CNS therapies for

    Mental/Nervous System Disorders. ................................................... 55 15-OD(ORDR)-101* Pilot projects for prevention, early detection and treatment of

    rare diseases. ..................................................................................... 56 15-OD(ORDR)-102* Collaborative translational research platform for rare diseases.

     56

    15-RR-101* Applied translational technology development. ..................................... 56 15-TW-101* Models to predict health effects of climate change. ........................... 56

    9

    Broad Challenge Area Specific Challenge Topic

    01-AA-101* Identifying Phenotypic Markers for Positive Behavior Change. (01) Behavior, Behavioral

    Change, and Prevention Identify reliable, robust intermediate phenotypic markers (using cognitive

    neuroscience and behavioral economics) that can be used to personalize approaches to support positive health behavior change in the near term. Examples include behavioral disinhibition, delay discounting, heart rate variability and implicit cognition. Contact: Dr.

    Mark Willenbring, 301-443-1208, mlw@niaaa.nih.gov

    01-AA-102* Functional Roles of Neuroimmune Factors in Mediating Behavior.

     Neuroimmune factors significantly impact both normal brain functions and a variety of

    neurological and behavioral disorders. Emerging data suggest that physiological

    functions of neuroimmune factors, such as cytokines and chemokines, are not restricted to mediating neuroinflammatory responses but may be considered as a new class of

    neurotransmitter, neuromodulator, or neurohormone in the brain. This paradigm shift

    offers a new framework to understand the roles of neuroimmune factors in a variety of behavioral conditions such as excessive drinking, anxiety, depression, etc. Contact: Dr.

    Antonio Noronha, 301-443-7722, anoronha@mail.nih.gov 01-AA-103* Capturing Social Network Information for Groups at High Risk for

    Negative Health Behaviors.

    Emerging evidence indicates that social networks influence health behaviors such as

    eating habits, alcohol consumption, and smoking. Research in this area is needed to

    enhance existing methodologies and/or devise novel methods that will capture social

    network information among groups at heightened risk for particular negative health

    behaviors. The ultimate public health goal is to use this information to influence

    behavioral choices and improve health outcomes. Contact: Dr. Mark Willenbring, 301-

    443-1208, mlw@niaaa.nih.gov

    01-GM-101* Individual-based model of social behavior. Development of a robust and well-characterized individual-based model of social behavior that includes the dynamics of social interactions and that matches observed

    patterns of behavior. Contact: Dr. Irene Eckstrand, 301-594-0943, eckstrai@nigms.nih.gov

    01-OD(OBSSR)-101* Tools for studying cultural phenomena. Development of new tools for: the measurement of culturally-shared mental phenomena (e.g., representations, scripts, prejudices); studying mechanisms by which these

    phenomena are transferred and adapted across individuals; and advancing research on the distribution and transmission of cultural phenomena within populations. Contact: Dr.

    Christine Bachrach, 301-496-9485, cbachrach@nih.gov NIAAA Contact: Dr. Marcia Scott, 301-402-6328, mscott@mail.nih.gov; NIAMS Contact: Dr. Susana Serrate-Sztein, 301-594-5032, NIAMShelp-NIHChallengeGrants@mail.nih.gov; FIC Contact: Dr. Aron Primack, 301-496-1653, aron_primack@nih.gov

    01-OD(OBSSR)-102* Methods for studying the interactions among behaviors,

    environments, and genetic/epigenetic processes.

    Research is needed to develop analytic methods, systems science approaches, or

    computational models designed to address the interactions among individual behaviors,

    social and physical environments and genetic/epigenetic processes during critical

    developmental periods and over time. This research is essential to incorporating the

    dynamic complexity of behavior and environments in the study of gene-environment interactions in health. Contact: Dr. Kay Wanke, 301-435-3718, wankek@od.nih.gov;

    10

Report this document

For any questions or suggestions please email
cust-service@docsford.com